PL3.F TuHURA Biosciences, Inc.

Healthcare Biotechnology Frankfurt Exchange
1.33 EUR
Close of Nov 12, 2026
0.3520 2.64
Market cap
EUR 84.8M
P/E
-
P/B
5.65x
ROE
-181.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PL3.F undervalued?

Graham number

The Graham number of TuHURA Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TuHURA Biosciences, Inc. fundamental analysis

No fundamental analysis for TuHURA Biosciences, Inc. yet.

TuHURA Biosciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta recep…

Full company profile